JFNNX — Janus Henderson Global Life Sciences Fund
Data updated: 2026-08-26
JFNNX — Janus Henderson Global Life Sciences Fund. United States Large Cap Growth Health Care Equity. Holdings, fees, performance and SEC filings.
JFNNX Fund Overview
JFNNX — Janus Henderson Global Life Sciences Fund is a US mutual fund managed by Janus Investment Fund, categorised as United States Large Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Janus Investment Fund
- Category: United States Large Cap Growth Health Care Equity
- Assets under management: $5.81B
- 1-year return: 39.6%
- Ticker: JFNNX
- SEC CIK: 0000277751
- SEC series ID: S000010494
- Share class ID: C000198286
JFNNX Holdings
Top 10 holdings of Janus Henderson Global Life Sciences Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Co. | 9.41% |
| Johnson & Johnson | 7.09% |
| AbbVie, Inc. | 4.67% |
| UnitedHealth Group, Inc. | 4.54% |
| AstraZeneca plc | 3.93% |
| Revolution Medicines, Inc. | 3.02% |
| Argenx SE | 2.63% |
| Novartis AG | 2.56% |
| Thermo Fisher Scientific, Inc. | 2.33% |
| Praxis Precision Medicines, Inc. | 2.19% |
JFNNX Portfolio Allocation
Asset-class allocation of Janus Henderson Global Life Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.1% |
| Cash & Equivalents | 0.9% |
JFNNX Performance
Total returns for JFNNX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 8.6% |
| 1 year | 39.6% |
| 3 years (annualised) | 13.6% |
| 5 years (annualised) | 8.7% |
JFNNX Risk Information
Risk metrics for JFNNX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 15.8%
JFNNX Costs and Fees
JFNNX costs about $68 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.68%
- Gross expense ratio: 0.68%
- Portfolio turnover: 30%
- Brokerage commissions: 2.61 bps of average net assets (SEC N-CEN)
JFNNX Cashflows
Over the 12 months to 2026-06, Janus Henderson Global Life Sciences Fund had net outflows of $20.46M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | −$26.64M |
| 2026-05 | −$11.89M |
| 2026-04 | −$12.19M |
| 2026-03 | $12.46M |
| 2026-02 | $33.34M |
| 2026-01 | −$6.42M |
JFNNX Debt Constituents
No individual debt constituents are reported in Janus Henderson Global Life Sciences Fund's latest SEC N-PORT filing.
JFNNX Prospectus and SEC Filings
Official Janus Henderson Global Life Sciences Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-01-28
- Prospectus (485BPOS) — filed 2025-01-28
- Prospectus (485BPOS) — filed 2024-01-26
- Portfolio holdings (N-PORT) — filed 2026-08-26
- Portfolio holdings (N-PORT) — filed 2026-05-29
- Portfolio holdings (N-PORT) — filed 2026-02-27
- Annual census (N-CEN) — filed 2024-12-13
- Annual census (N-CEN) — filed 2023-12-14
Related Funds
Other United States Large Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.